Where is Cellero located?

Cellero is headquartered in Lowell, United States.

How many employees does Cellero have?

As of Jul 01, 2024, the latest employee count at Cellero is 3.

Is Cellero a funded company?

Cellero is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Cellero rank among its competitors?

Cellero ranks 1968th amongst 1949 active competitors, of which 452 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Life Biosciences, which secured $80M in Apr, 2026.

Who are the top competitors of Cellero?

Cellero's top competitors include Synthego, Antheia and Transcenta. Among them, Life Biosciences secured the most recent funding round in April, 2026.

Cellero - 2026 Company Profile, Funding & Competitors

Cellero is an acquired company based in Lowell (United States), founded in 2004. It operates as a Developer of biomaterials, immune cell products for multiple health purposes. The company has 1949 active competitors, including 452 funded and 335 that have exited. Its top competitors include companies like Synthego, Antheia and Transcenta.

Company Details

Developer of biomaterials, immune cell products for multiple health purposes. The company's proprietary platform involves research services and offers cryopreserved human immune cells, leukoplakia, and other blood products. It provides multiple services like assay development, product development, contract research, collection services, and others. Products include apheresis-derived platelets, whole blood, packed red blood cells, small volume whole blood samples, frozen leukoplakias, and many more.

Website: cellero.com
Social
Email ID: *****@cellero.com
Phone Number: +1 **********

Key Metrics

Founded Year

2004

Location

Lowell, United States

Stage

Acquired

Investors

Ampersand Capital

Ranked

1968^th among 2661 competitors

Employee Count

3 as on Jul 01, 2024

Similar Companies

Synthego & 2659 more

Exit Details

Acquired by Charles River Laboratories (Aug 01, 2020)

View Cellero's full profile

Cellero got acquired by Charles River Laboratories on Aug 01, 2020 at an acquisition amount of $*****.

Click here to take a look at Cellero's acquisition in detail

Cellero is a funded company. Cellero has 1 institutional investor.

View details of Cellero's funding rounds and investors

Cellero's employee count trend

Cellero has 3 employees as of Jul 24. Here is Cellero's employee count trend over the years:

Uncover Cellero's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cellero include Synthego, Antheia and Transcenta. Here is the list of Top 10 competitors of Cellero, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
5th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Fidelity Investments, Monashee Investment Management ... & 14 others	64/100
6th	Life Biosciences 2017, Boston (United States), Series D	Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases	$261M	Alpha Wave Global, Globalive Capital & 12 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 12 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
9th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$346M	Maverick Ventures, SoftBank Vision Fund & 15 others	62/100
10th	enGene 1999, Saint laurent (Canada), Public	Developer of oral non-viral gene therapy platform	$54M	Hercules Capital, Lumira Ventures & 15 others	62/100
1968th	Cellero 2004, Lowell (United States), Acquired	Developer of biomaterials, immune cell products for multiple health purposes	-	Ampersand Capital	19/100